Ambev S.A.
3.01USD
-0.0300 (-0.99%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.04▼ | $0.05 | 0 | 3 |
| Next quarter | $0.06▼ | $0.06 | 0 | 2 |
| Current year | $0.2▲ | $0.2 | 5 | 1 |
| Next year | $0.21▼ | $0.22 | 2 | 4 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.03 | $0.04 | +0.01 (+24.9%) |
| 2026-03-31 | $0.04 | $0.05 | +0.01 (+14.0%) |
| 2025-12-31 | $0.05 | $0.05 | -0.00 (-0.9%) |
| 2025-09-30 | $0.04 | $0.04 | +0.00 (+9.6%) |
52 ratings from 14 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Scotiabank | Downgraded from Sector Outperform | Sector Perform | — | Jul 15, 2026 |
| UBS | Maintained | Sell | $2.65 $2.9 | May 14, 2026 |
| Barclays | Maintained | Equal-Weight | $3 $3.5 | May 6, 2026 |
| UBS | Downgraded from Neutral | Sell | — | Apr 16, 2026 |
| Barclays | Maintained | Equal-Weight | $2.5 $3 | Feb 17, 2026 |
| Bernstein | Downgraded from Outperform | Market Perform | $2.88 | Nov 26, 2025 |
| UBS | Maintained | Neutral | $2.5 $2.2 | Aug 20, 2025 |
| HSBC | Downgraded from Buy | Hold | — | Aug 1, 2025 |
| UBS | Maintained | Neutral | $2.6 $2.7 | Jun 4, 2025 |
| Barclays | Maintained | Equal-Weight | $2 $2.5 | May 12, 2025 |
| UBS | Downgraded from Buy | Neutral | — | Apr 22, 2025 |
| Morgan Stanley | Downgraded from Equal-Weight | Underweight | — | Apr 7, 2025 |
| UBS | Maintained | Buy | $2.9 $2.6 | Mar 5, 2025 |
| Citigroup | Downgraded from Buy | Neutral | — | Jan 22, 2025 |
| Barclays | Maintained | Equal-Weight | $2.5 $2 | Jan 21, 2025 |
| UBS | Maintained | Buy | $3.2 $2.9 | Jul 31, 2024 |
| Barclays | Maintained | Equal-Weight | $3 $2.5 | May 9, 2024 |
| Barclays | Downgraded from Overweight | Equal-Weight | $3.5 $3 | Mar 4, 2024 |
| Jefferies | Initiated | Hold | $2.86 | Nov 22, 2023 |
| Bernstein | Initiated | Outperform | $3.74 | May 24, 2023 |
| JP Morgan | Upgraded from Neutral | Overweight | — | Jul 13, 2022 |
| B of A Securities | Upgraded from Underperform | Neutral | — | Nov 3, 2021 |
| Barclays | Upgraded from Equal-Weight | Overweight | $4 $3.5 | Oct 6, 2021 |
| Barclays | Upgraded from Underweight | Equal-Weight | $2.5 $4 | Jun 17, 2021 |
| Itau BBA | Downgraded from Outperform | Market Perform | $3.6 | May 20, 2021 |
No analyst notes on ABEV yet.
Analyst Ratings
10 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 1 | 6 | 2 | 0 | Hold2.73 |
| 1 mo ago | 2 | 1 | 6 | 2 | 0 | Hold2.73 |
| 2 mo ago | 2 | 1 | 6 | 2 | 0 | Hold2.73 |
| 3 mo ago | 2 | 1 | 6 | 2 | 0 | Hold2.73 |